Kitty
Senior Member (Voting Rights)
I am not saying that monitoring specific activities is not a useful tool, but which activities selected is highly significant as the act of selecting them will give them an increased importance.
That's a really important point, but (and I know I sound contrary!) I'm still not sure it matters. At least, not in the scenario I'm trying to work through.
The question I'm trying to anticipate is: does this treatment act on the underlying disease process in ME/CFS?
If it doesn't it should be reasonably obvious. Level 1 activities are there to show where the individual started pre-treatment, but they're not an outcome measure; the trial is looking for sustained progression to level 2 and 3 activities. That won't show up across the cohort if the treatment fails.
If it does work, the choices people have to make about minor daily living activities will fall away. Trying to juggle level 1 activities should become history, like trying to shower without getting the cast wet that time you broke your ankle.
The line of thought began after re-reading concerns about what happens if a trial shows a result so strong it seems likely the team's begun to unpick the lock. They have something that already exists and could potentially get people out of darkened rooms, but it needs replication on a bigger cohort.
I'm anticipating that trial. How do we set the outcomes so that a genuinely positive result is as convincing to sceptical doctors and grant panels as we can make it? Participants reporting how they feel might not be enough, even if backed up by other measures. Showing how their activity pattern changed—potentially drastically in some cases—might be.